Conclusions from the VA-HIT study

American Journal of Cardiology

Volumn 86, Issue 5, 2000, Pages 543-544

  Rubins, Hanna Bloomfield ^a   Robins, Sander J ^b  

^a VA MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034284449     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01010-9     Document Type: Note

References (16)

1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;:16-19.
2. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
3. Young S.G., Fielding C.J. The ABC's of cholesterol efflux. Nature Genetics. 22:1999;316-318.
4. Rigotti A., Krieger M. Getting a handle on "good" cholesterol with the high-density lipoprotein receptor. N Engl J Med. 341:1999;2011-2013.
5. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
6. Rubins H.B., Robins S.J., Collins D., Iranmanesh A., Wilt T.J., Mann D., Mayo-Smith M., Faas F.H., Elam M.B., Rutan G.H., Anderson J.W., Kashyap M.L., Schectman G. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 75:1995;1196-1201.
7. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
8. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., Houston-Miller N., Kris-Etherton P., Krumholz H.M., LaRosa J., Ochene I.S., Pearson T.A., Reed J., Smith S.C., Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on risk reduction. Circulation. 95:1997;1683-1685.
9. Sacks F.M., Moye L.A., Davis B.R., Cole T.G., Rouleau J.L., Nash D.T., Pfeffer M.A., Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 97:1998;1446-1452.
10. Sacks FM, Braunwald E, Simes J, Packard C, Shepherd J, Furberg CD, Tonkin AM. Pretreatment lipid concentrations and coronary event reduction with pravastatin: The prava-3 pooling project. Circulation 199;(suppl I):I-100:739.
11. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at inceased risk of coronary heart disease death:early safety and efficacy experience. Eur Heart J. 20:1999;725-741.
12. Rubins H.B., Robins S.J., Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol . Am J Cardiol. 78:1996;572-575.
13. Liese A.D., Mayer-Davis E.J., Haffner S.M. Development of the multiple metabolic syndrome:An epidemiologic perspective. Epidemiol Rev. 20:1998;157-172.
14. Tenkanen L., Manttari M., Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 92:1995;1779-1785.
15. The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation, in press.
16. Down J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.